Literature DB >> 17497143

Lamotrigine in children and adolescents: the impact of age on its serum concentrations and on the extent of drug interactions.

Arne Reimers1, Eirik Skogvoll, Janne Kutschera Sund, Olav Spigset.   

Abstract

OBJECTIVE: To investigate the impact of age and co-treatment with other drugs on the serum concentrations of lamotrigine in children and adolescents.
METHODS: A review of routine serum concentration measurements of lamotrigine performed in our laboratory yielded a total of 744 serum samples from 296 subjects (110 males, 186 females, age: 2-19 years) suitable for statistical analysis. The primary outcome variable was the dose-corrected lamotrigine serum concentration, expressed as the lamotrigine concentration/dose (C/D) ratio. A linear mixed model that allowed multiple observations from the same patient was used to identify and quantify the effect of factors influencing the lamotrigine C/D ratio.
RESULTS: According to the model, the lamotrigine C/D ratio decreases by 6% per year of age. Valproate and levetiracetam were found to raise the lamotrigine C/D ratio, whereas the following co-medications reduced it: carbamazepine, clobazam, fluoxetine, clonazepam and ethinyl estradiol. The effect of carbamazepine decreased with increasing age. No gender difference was detected.
CONCLUSIONS: Age is an important factor with respect to the pharmacokinetics and the extent of drug interactions of lamotrigine in children and adolescents. In this population, older individuals will need higher doses than younger ones in order to achieve the same serum concentrations.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17497143     DOI: 10.1007/s00228-007-0308-2

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   3.064


  32 in total

Review 1.  Glucuronidation in humans. Pharmacogenetic and developmental aspects.

Authors:  S N de Wildt; G L Kearns; J S Leeder; J N van den Anker
Journal:  Clin Pharmacokinet       Date:  1999-06       Impact factor: 6.447

2.  When thinking of lamotrigine and valproic acid, think "pharmacokinetically"!

Authors:  Andres M Kanner
Journal:  Epilepsy Curr       Date:  2004 Sep-Oct       Impact factor: 7.500

3.  Drug interactions between lamotrigine and psychoactive drugs: evidence from a therapeutic drug monitoring service.

Authors:  Arne Reimers; Eirik Skogvoll; Janne Kutschera Sund; Olav Spigset
Journal:  J Clin Psychopharmacol       Date:  2005-08       Impact factor: 3.153

4.  Experiences with Bivotril in treatment of epilepsy--particularly minor motor epilepsy--in mentally retarded children.

Authors:  O Eeg-Olofsson
Journal:  Acta Neurol Scand Suppl       Date:  1973

5.  Lamotrigine serum concentration-to-dose ratio: influence of age and concomitant antiepileptic drugs and dosage implications.

Authors:  J A Armijo; J Bravo; A Cuadrado; J L Herranz
Journal:  Ther Drug Monit       Date:  1999-04       Impact factor: 3.681

6.  Pharmacokinetics of lamotrigine in children in the absence of other antiepileptic drugs.

Authors:  C Chen; E J Casale; B Duncan; E H Culverhouse; J Gilman
Journal:  Pharmacotherapy       Date:  1999-04       Impact factor: 4.705

7.  Developmental aspects of human hepatic drug glucuronidation in young children and adults.

Authors:  C P Strassburg; A Strassburg; S Kneip; A Barut; R H Tukey; B Rodeck; M P Manns
Journal:  Gut       Date:  2002-02       Impact factor: 23.059

8.  Single-dose pharmacokinetics of lamotrigine in children: influence of age and antiepileptic comedication.

Authors:  D Battino; D Croci; T Granata; D Mamoli; S Messina; E Perucca
Journal:  Ther Drug Monit       Date:  2001-06       Impact factor: 3.681

Review 9.  Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism.

Authors:  S H Preskorn
Journal:  Clin Pharmacokinet       Date:  1997       Impact factor: 6.447

10.  Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs.

Authors:  Sven Björkman
Journal:  Br J Clin Pharmacol       Date:  2005-06       Impact factor: 4.335

View more
  5 in total

1.  Effect of Age-Related Factors on the Pharmacokinetics of Lamotrigine and Potential Implications for Maintenance Dose Optimisation in Future Clinical Trials.

Authors:  Sven C van Dijkman; Nico C B de Jager; Willem M Rauwé; Meindert Danhof; Oscar Della Pasqua
Journal:  Clin Pharmacokinet       Date:  2018-08       Impact factor: 6.447

2.  Oxcarbazepine oral suspension in pediatric patients with partial seizures and/or generalized tonic-clonic seizures: a multi-center, single arm, observational study in China.

Authors:  Yi Wang; Yin-Bo Chen; Yu-Qin Zhang; Rong Luo; Hua Wang; Jun-Lan Lv; Dong Wang; Sui-Qiang Zhu; Zhong-Dong Lin; Jiong Qin
Journal:  World J Pediatr       Date:  2017-06-22       Impact factor: 2.764

3.  Pharmacokinetics of lamotrigine and its metabolite N-2-glucuronide: Influence of polymorphism of UDP-glucuronosyltransferases and drug transporters.

Authors:  Daniela Milosheska; Bogdan Lorber; Tomaž Vovk; Matej Kastelic; Vita Dolžan; Iztok Grabnar
Journal:  Br J Clin Pharmacol       Date:  2016-05-29       Impact factor: 4.335

Review 4.  Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age: an update.

Authors:  Domenico Italiano; Emilio Perucca
Journal:  Clin Pharmacokinet       Date:  2013-08       Impact factor: 6.447

5.  Pharmacokinetics of lamotrigine in paediatric and young adult epileptic patients--nonlinear mixed effects modelling approach.

Authors:  Branka Brzaković; Katarina Vučićević; Sandra Vezmar Kovačević; Branislava Miljković; Milica Prostran; Žarko Martinović; Milena Pokrajac
Journal:  Eur J Clin Pharmacol       Date:  2013-11-19       Impact factor: 2.953

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.